Success Metrics

Completion Rate
0%(0/1)
Active Trials
2(50%)
Terminated
1(25%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
3
75%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Terminated(1)
Other(1)

Detailed Status

Recruiting2
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

recruiting250%
terminated125%
unknown125%

Recent Activity

2 active trials
Showing 4 of 4
terminatedphase_1

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

NCT05300048
recruitingphase_1

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

NCT07558733
recruitingphase_2

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

NCT06463028
unknownphase_1

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

NCT04073680

Clinical Trials (4)

Showing 4 of 4 trials
NCT05300048Phase 1

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Terminated
NCT07558733Phase 1

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Recruiting
NCT06463028Phase 2

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Recruiting
NCT04073680Phase 1

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4